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Summary: Commercial luminescence enhanced enzyme immunoassays (Amersham-Amerlite) for thyroxine
binding globulin (TBG) and total thyroxine (TT4) were compared with the in-house methods (TT4 — Abbott
TDx, TBG — Immunoluminometric Assay (ILMA)).
The experimental groups consisted of 108 healthy euthyroid blood donors, 165 non-selected thyroid outpa-
tients, 44 tumour bearers and 84 haemodialysis patients.
Total thyroxine/thyroxine binding globulin quotients were constructed as an index of thyroid function.
The luminescence enhanced enzyme immunoassays were precise (interassay coefficients of variation less than
10% in the range 5—45mg/l thyroxine binding globulin and 20 —100 μg/l for total thyroxine) performed
similarly to the in-house methods in the differentiation of eu-, hypo- and hyperthyroidism on the basis of
total thyroxine/thyroxine binding globulin quotients. Although statistically significant differences often oc-
curred in comparisons of the in-house method with the luminescence enhanced enzyme immunoassays, these
only gave rise to thyroid status differences in two cases out of 273, where the in-house method gave a
hyperthyroid, the luminescence enhanced enzyme immunoassay a euthyroid answer, when taken from the
total thyroxine/thyroxine binding globulin quotients.
The luminescence enhanced enzyme immunoassays performed as well as the in-house methods, and quality
assessment data were comparable with their radioimmunological counterparts.
ine/thyroxine binding globulin quotients were then
The trend towards the increased use of non-radioiso- constructed.
topic immunoassays continues; the present article de- A 4, .. r . ... , , <ΛΟ.. . . *" *' . n .. « t A euthyroid reference range was established on 108scribes the comparison of a commercially available ,, , j: .. - ,.. ., „ ,
t Γ - . / A blood donors with normal thyroid parameters (basalluminescence enhanced enzyme immunoassay (Amer- ., . ' . , .. , 4, · \ j- T . IN . . . t · ι · thyrotropin, thyroxine and tmodothyronine) and nor-sham International) with an in-house immunolumi- , · / r j 1 * 1 * +·Α
x . ' " ' „ Ν * -.L j -. · *· * ̂  · ma^ aminotransferases and γ-glutamyl transpeptidasenometnc assay (1) for the determination of thyroxine , . _ Λ 4 ,, , ,' ° t j-j * r in- . ,. , , i- - τ j Λ, - j levels. Forty two blood donors who did not fulfilbinding globulin in serum. In order to assess thyroid - . / . . - r .-& f . t , . these criteria were excluded from the group,status, thyroxine values were also measured, using
both luminescence enhanced enzyme immunoassay Patients were selected from the dialysis clinic, as it is
(Amersham International) and fluorescence polaris- known that dialysis patients often have anomalous
ation immunoassay (Abbott Laboratories). Thyrox- results due, amongst other things, to dysproteinaemia
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(2). Other experimental groups included tumour bear-
ers and non-selected patients attending the thyroid
outpatient clinic.
The aim of the study was to see whether the new kit
was able to assess thyroid status, when used in con-
junction with other relevant thyroid parameters.
Materials and Methods
The luminescence enhanced immunoassay kits for total thyrox-
ine and thyroxine binding globulin (Amerlite) were donated by
Amersham-Buchler, Braunschweig, D. The fluorescence-polar-
isation immunoassay for total thyroxine (Abbott TDx) was
from Abbott, Diagnostics Wiesbaden-Delkenheim, D.
The immunoluminometric assay for thyroxine binding globulin
was the in-house assay and has been described elsewhere (1).
The Amerlite Assays were set up manually and were processed
on the Amerlite washer and measuring/processing unit (tab. 1 a
+ Ib).
The Abbott TDx Assay was performed according to the man-
ufacturer's instructions (tab. 1 c) and the immunoluminometric
assay was performed as described in table 1 d. Patient samples
were obtained from the routine laboratory of this department
and from the blood bank of the hospital.
Tab. 1 a. Flow scheme of the Amerlite — TBG Assay
10 μΐ sample/standard in antibody coated well,
100 μΐ labelled antigen (peroxidase),
100 μΐ assay reagent buffer.
Incubate 30 minutes at 37 °C,
wash, add 250 μΐ signal reagent to each well,
wait 5 minutes, measure in
Amerlite luminometer and await results
Tab. 1 b. Flow scheme of the Amerlite TT4 Assay
10 μΐ sample/standard into antibody coated well,
100 μΐ labelled antigen (peroxidase),
100 μΐ assay reagent buffer.
Incubate 60 minutes at 37 °C,
wash and add 250 μΐ signal reagent,
wait 5 minutes, measure and await results.
Tab. 1 c. Flow scheme of the Abbott TDx TT4 Assay
100 μΐ sample in sample cup.
Insert with control sera and reagents into analyser;
await results.
Tab. 1 d. Flow scheme of the Immunolumetric Assay for thy-
roxine binding globulin
25 μΐ sample/standard (1:250 dilution),
200 μΐ (ABEN-H)-labelled antibody to thyroxine binding glob-
ulin,
1 anti-thyroxine binding globulin coated ball.
Incubate 60 minutes in rotator (170 min"1)»
wash with 2 χ 5 ml 0.25 ml/1 Tween 20,
transfer ball to measuring cuvette, add catalyst, initiate light
reaction with alkaline peroxide and integrate signal over 4 s.
ABEN-H = N-(4-aminobutyl)-N-ethylisoluminol hemisuccin-
amide
For comparison, the thyroxine binding globulin standards from
the Amerlite Kit were used in both Amerlite and ILMA meth-
ods.
Patients were divided into 3 groups — thyroid outpatients
(n = 165), tumour bearers (n = 44) (clinically or surgically
confirmed cases) and dialysis clinic (n = 84). Reference ranges
were set up from 108 blood donor sera.
• ι
Non-parametric statistics were used throughout as certain data
were not normally distributed (mean/median ratio 0.95 — 1.05
by unimodal distribution). Results were expressed as percentiles
and the mid-range as the median. The mean/median ratio was
used to express skewness. The Wilooxon signed rank-test with
C-Alpha calculation was used for paired data, the Mann Whit-
ney U-Test for non-paired data. Correlations were calculated
from normal or near-normally distributed data.
Results
The results are presented, as far as possible, in tabular
form to save space and give an easy-to-^read format.
Sera which were lipaernic, haemolytic or icteric were
noted to check the effects of these conditions on the
assays. As no difference in results by different meth-
ods was seen, no special statistical treatment of such
sera was made. The total thyroxine/thyroxine binding
globulin quotient for serum is calculated from total
thyroxine in μg/l and thyroxine binding globulin in
mg/1. Detailed clinical data on the patient groups has
been kept to a minimum, especially for the hetero-
geneous thyroid-outpatient group. It must be noted
that the median age of the experimental groups is
different from the reference group of blood-donors.
This was practically unavoidable without extensive
screening of all groups. This has no effect on the total
thyroxine/thyroxine binding globulin quotients, which
have been reported to remain constant throughout
life (3).
Age distribution in the different groups
Table 2 shows the age ranges and relevant percentiles
in each of the experimental groups.
Tab. 2. Age distribution in the different groups
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Tab. 3. Distribution of thyroxine binding globulin values —
Amerlite and Comparison method in the 4 Groups.






















































































Tab. 4. Distribution of total
groups
thyroxine values in the different













































































Distribution of thyroxine binding globulin
and total thyroxine values
Table 3 shows the distribution of the thyroxine bind-
ing globulin values in both methods. Table 4 shows
the same data for the total thyroxine serum concen-
trations.
Tab. 5. Correlation between routine assays and Amerlite assays,
(x = routine, y = Amerlite where not stated otherwise)
Correlation between both methods
The correlation between the thyroxine binding glob-
ulin and total thyroxine concentrations in the relevant
groups is given in table 5. Table 6 shows the non-
parametric statistics for the differences in thyroxine
binding globulin and total thyroxine concentrations
found in the experimental groups as compared with
the blood donors.
Group n r al bl a2 b2 pt sig

























































4. Amerlite TT4 2 min v 12 min
60 0.99 11.5 1.09 -8.91 0.89 -20.8 s
Key:
The regression lines represent the equations y == al 4- blx and χ = a2 + b2y.
pt — paired lvalue.
sig -- significance, ns = not significant, s = significant.
0 with an alternative pair of antibodies, the anomalous results were not longer present, the regression data being as follows for
the dialysis patients: n = 85, r = 0.82, al = 3.27, bl = 0.81, a2 = 2.79, b2 = 0.91, pt = 1.04, ns.
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Tab. 6. Comparison of groups using the Mann-Whitney U-test
with z-transformation
1. TBG Amerlite
Blood donors v Dialysis — z
Blood donors v Thyroid — z
Blood donors v Tumour — z
2. TT4 Amerlite
Blood donors v Dialysis — z
Blood donors v Thyroid — z
Blood donors v Tumour — z
3. TBG ILMA
Blood donors v Dialysis — z
Blood donors v Thyroid — z
6.30 (s) p < 0.01
3.52 (s) p < 0.01
-1.74(ns)p > 0.05
3.01 (s) p = 0.01
-5.41 (s) p < 0.01
-2.28 (s) p < 0.05
2.96 (p = 0.01)
-1.45(ns)(p > 0.05)
4. TT4 Abbott
Blood donors v Thyroid - z = -4.39 (s) (p < 0.01)
s — significant difference
ns — no significant difference
Thyroxine/thyroxine binding globulin
Thyroxine/thyroxine binding globulin quotients were
calculated because no "free thyroxine" determination
was available from either Abbott or Amersham which
used a non-radioisotopic label. Table 7 shows the
distribution of thyroxine/thyroxine binding globulin
ratios, calculated as stated in the materials and meth-
ods section above.























































































Table 8 shows the statistical differences in the thyrox-
ine/thyroxine binding globulin ratios, expressed
against the blood donors as controls, From table 7,
the reference range of the thyroxine/thyroxine binding
globulin ratio in the Amerlite system is from 1.00—
5.82 (95% confidence-limits) and for the ILMA/Ab-
bott combination 1.20 -5.68. Table'9 shows the co-
incidence of the thyroxine/thyroxine binding globulin
ratio in both methods using the reference ranges
above. From this table it can be seen that the discrimr
ination of both methods is similar for the thyroid
outpatients group, and that in both unselected tumour
and dialysis patients, a euthyroid status is predomi-
nant according to the total thyroxine/thyroxine bind-
ing globulin ratios. The numerical value of the total
thyroxine binding globulin ratios was significantly
different in both methods as can be seen in table 10,
but this did not affect the classification into eu-, hypo^
or hyperthyroid groups.
Tab. 8. Comparison of total thyroxine/thyroxine binding glob-
.ulin ratios on the different groups as compared with
the reference group. Using the Mann-Whitney U-test
with z-transformation
a) Amersham
Blood donors v Dialysis z
Blood donors v Thyroid z
Blood donors v Tumour z
b) ILMA/Abbott
a. Blood donors v z
Thyroid
b.*) Blood donors v z
Thyroid
^3.85 (s) p < 0.01
-7.18 (s) p < 0.01
-0.06 (ns) p > 0.05
-1.57(ns)p > 0.05 (n = 165)
-0.80 (ns) p < 0.05 (n = 105)
*) on the same 105 patients as measured with the Amersham
assays.
Tab. 9. Coincidence of total thyroxine/thyroxine binding glob-
ulin ratios in the different experimental groups
a) Amersham
a Hypothyroid (< 1.00)
b Euthyroid (1.00-5.82)
c Hyperthyroid > 5.82
b) ILMA/Abbott
a Hypothyroid (< 1.2)
b Euthyroid (1.2 -5.68)
e Hyperthyroid
Dialysis Thyroid
















Using the same 105 patients as in the Amersham kit.
J f ^
*) For «comparison, the same 105 patients were measured in
both assays.
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Tab. 10. Statistical comparison of total thyroxine/thyroxine














108) ce = 5.62 ρ






ayx = 0.468 byx = 0.62

















The intra- and inter-assay coefficients of variation are
shown in table 11 for the Amerlite kits. These were
determined in the usual way i.e. with 20 measure-
ments of the control serum in one assay, or from
duplicate measurements of the serum in 20 consecu-
tive assays. The interassay coefficient of variation of
the Abbott TT4 assay was 8.7% at 88 μg/l and 8.5%
at 25.4 mg/1 for the TBG ILMA. Intraassay coeffi-
cients of variation were not calculated for the Abbott
TT4 assay as samples were run without replicates. The
mean intraassay coefficient of variation for the TBG
ILMA in the range 10 — 50 mg/1 was 5.3%, these
figures being derived from precision profiles in which
672 values were taken from 34 assays.
Lower detection limits of the Amerlite TBG
and TT4 kits
The lower detection limits of the assays were deter-
mined, despite the fact that these were clinically ir-
relevant. The thyroxine binding globulin assay had a
lower detection limit below 3 mg/1 and the total thy-
roxine assay below 15 μ§/1. The data in table 11
indirectly support these figures. These data show that
both assays are suited for routine use, even in the
detection of radically reduced thyroxine binding glob^
ulin concentrations found in hereditary cases of thy-
roxine binding globulin deficiency.
Discussion
The continuous introduction of non-radioisotopic
methods into in-vitro thyroid diagnosis, using both
open and closed systems, makes an evaluation of such
methods necessary, especially with respect to clinical
usefulness.
Tab. 11. Quality control parameters for the Amerlite system
a) Intra-assay





















































Thyroxine binding globulin (mg/1)
Serum 1 20 5.73 0.568
2 20 18.2 1.28
3 20 43.8 3.28
Total thyroxine (\ig/\)
Serum 1 20 23.9 2.20
2 20 52.6 4.29















* Serum 1—3 were pool sera supplied with the kits.
** Serum 4 + 5 were single patient sera from the routine
laboratory
With the introduction of TBG, the Amerlite system
now has a full thyroid programme consisting of thy-
rotropin, triiodothyronine, thyroxine binding globulin
and thyroxine, thus allowing surveillance at the pi-
tuitary, thyroid and peripheral levels.
Although the in-house and Amersham methods some-
times gave different analytical values, the clinical
interpretation of the results — as reflected in tables
7—9 was similar.
The lower detection limits of the assay were excellent
(see tab. 11 for indirect evidence) and are fully com-
parable with those of radioimmunological methods.
The quality control data (tab. 11) shows the "alter-
native methods" also to be equivalent to the best
radioimmunological ones.
The total thyroxine/thyroxine binding globulin quo-
tients in the euthyroid range were comparable to those
obtained by most other published methods (3).
The absence of large numbers of hypo- or hyperthy-
roid patients may be due to the fact that the majority
of patients attending the outpatient clinic were under
medication for their thyroid disorder. The limited
value of in-vitro tests in such cases has been discussed
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at length, with arguments expressed against unnec-
cessary in-vitro tests (4, 5) and in favour (6) of such
testing. This point will not be further discussed here,
as it lines outside the scope and aims of the study.
Until the measurement of "free thyroxine" has been
standardised with respect to methodology and refer-
ence ranges, there is still a valid argument for the
construction of total thyroxine/thyroxine binding
globulin quotients to assess thyroid status (7—9).
Since much in-vitro testing is performed in labora-
tories where the patient is unknown, the present study
has concentrated on the quality of the tests, rather
than details about specific groups of patients, for
example with „non-thyroidal illness", or the question
of whether in-vivo or in-vitro heparin affects the re-
sults. It is important to note that lipaemia, haemolysis
and hyperbilirubinaemia do not adversely affect re-
sults, when compared with the routine methods used
in this study.
The light signal of the Amersham assays was stable
for relatively long periods of time, thus allowing de-
layed or repeated measurements of samples.
Although the numerical values were statistically dif-
ferent (see tab. 8), this was only marginally relevant
and was due to curve^fitting rather than to differential
deterioration of samples. As shown in a prior com-
munication from this laboratory (10), in which a
luminescence enhanced enzyme immunoassay for car-
cinoembryomic antigen was evaluated, this type of
assay is ready for routine use and offers a real routine
alternative to radioimmunological methods.
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